Printer Friendly

Oliceridine Studied for IV Pain Relief After Abdominoplasty; Findings published from phase III trial of patients with moderate-to-severe acute postoperative pain.

THURSDAY, July 11, 2019 (HealthDay News) -- Oliceridine is being proposed as an analgesic option for the relief of moderate-to-severe acute postoperative pain, according to a study recently published in Pain Practice.

Neil K. Singla, M.D., from Lotus Clinical Research in Pasadena, California, and colleagues randomly assigned 401 patients with moderate-to-severe acute postoperative pain following abdominoplasty to a loading dose of placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses administered through patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine; 1 mg morphine; or placebo) with a six-minute lockout interval.

The researchers found that effective analgesia was achieved with all oliceridine regimens, with responder rates of 61.0 percent for the 0.1-mg demand dose regimen, 76.3 percent for the 0.35-mg regimen, and 70.0 percent for the 0.5-mg regimen versus 45.7 percent for placebo and 78.3 percent for morphine. Equivalent analgesic effect was seen for oliceridine 0.35- and 0.5-mg regimens, compared with morphine. The respiratory safety burden (RSB) demonstrated a dose-dependent increase across oliceridine regimens (mean hours, 0.1 mg: 0.43; 0.35 mg: 1.48; 0.5 mg: 1.59, compared with placebo [0.60]; the RSB measure for morphine was 1.72). There was also a dose-dependent increase in gastrointestinal adverse events across oliceridine demand dose regimens (0.1 mg: 49.4 percent; 0.35 mg: 65.8 percent; 0.5 mg: 78.8 percent, compared with placebo [47.0 percent] and morphine [79.3 percent]). However, the proportion of patients experiencing nausea or vomiting was lower with 0.35- and 0.5-mg oliceridine versus morphine.

"These findings support that oliceridine may provide a new treatment option for patients with moderate-to-severe acute pain where an intravenous opioid is warranted," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Trevena, which manufactures oliceridine and sponsored the study.

Abstract/Full Text

COPYRIGHT 2019 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Article Type:Clinical report
Date:Jul 11, 2019
Previous Article:Medicare Drug Rebate Plan Withdrawn by Trump Administration; Rebates would have been paid directly to seniors in Medicare Part D program when they...
Next Article:Elderly-Onset Rheumatoid Arthritis Ups Bone Erosion Risk; Even two years of clinical remission does not protect against bone erosions.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters